- The P-III NEPTUNE study involves assessing of Imfinzi + tremelimumab vs SOC platinum-based CT as a 1L treatment in patients with Stage IV metastatic NSCLC + high tumor mutational burden (TMB) across 29 countries including the US, Europe, South and Central America, the Middle East and Asia.
- The P-III NEPTUNE study results demonstrated that it did not meet 1EPs i.e, OS in patients with high blood TMB defined as ≥ 20 mut/Mb while its safety and tolerability profile is consistent with previous studies
- Imfinzi is a mAb targeting PD-L1, blocking its interaction with PD-1 and CD80, currently being evaluated in P-III PEARL study as monothx. and in combination with CT with/out tremelimumab in the P-III POSEIDON for Stage IV NSCLC
Click here to read full press release/ article | Ref: AstraZeneca| Image: Coroflot